Evidence map›Paper›PMID 29943192›Full record

Trial reportCancer chemotherapy and pharmacology2018

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma.

John P Fruehauf, Monica El-Masry, Katherine Osann, Basmina Parmakhtiar, Maki Yamamoto, James G Jakowatz

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer chemotherapy and pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01107665 (A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01107665 phase2completednot on this map

A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

TypeinterventionalSponsorUniversity of California, IrvineRan2010 to 2018Enrolled60ConditionsStage III Melanoma, Stage IV Melanoma, Unresectable MelanomaArmsPazopanib and Paclitaxel
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Hypoxia-dependent drivers of melanoma progression.Journal of experimental & clinical cancer research : CR · 2021
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John P FruehaufDivision of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA. jfruehau@uci.edu.ORCID 0000-0002-9447-9440
Monica El-MasryDivision of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA.
Katherine OsannDivision of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA.
Basmina ParmakhtiarDivision of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA.
Maki YamamotoDivision of Surgical Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA.
James G JakowatzDivision of Surgical Oncology, Chao Family Comprehensive Cancer Center, University of California, 101 The City Drive South, Bldg 56, Orange, Irvine, CA, 92868, USA.
University of California, Irvine Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis phase II study evaluated the safety and clinical activity of pazopanib, a potent and mutlitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs)-1, -2 and -3, platelet-derived growth factor receptor (PDGFR)-α and β, and cKit, in combination with metronomic paclitaxel in patients with metastatic melanoma. EXPERIMENTAL

designSixty chemotherapy-naive patients received pazopanib at a starting dose of 800 mg daily in combination with metronomic dosing of paclitaxel 80 mg/m

resultsThe 6-month PFS rate was 68%, with a 1-year OS rate of 48%. Objective response rate was 37% comprising one complete and 20 partial responses. Stable disease at 8 weeks was noted in 32 patients (55%) with an overall clinical benefit rate of 93%. Six-month median progression-free survival was 8 months and median OS was 12.7 months. The most frequently (> 15%) reported non-hematologic, treatment-related adverse events were fatigue, diarrhea, hypertension, transaminitis and peripheral neuropathy. Treatment-related non-fatal bowel perforation, a known class effect, occurred in one patient. No significant association was noted between plasma levels of pazopanib and response.

conclusionsThe combination of pazopanib and metronomic paclitaxel was well-tolerated, demonstrating significant activity in metastatic melanoma. Further evaluation of this combination is warranted.

Indexed as

Administration, MetronomicAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansIndazolesKaplan-Meier EstimateMaleMelanomaMiddle AgedNeoplasm StagingPaclitaxelProgression-Free SurvivalPyrimidinesIndazolesPaclitaxelpazopanibPyrimidinesSulfonamidesAntiangiogenic agentBRAFMetastatic melanomaMetronomic paclitaxelPazopanib

Identifiers

PMID29943192
PMCPMC6060847
OpenAlexW2810718021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.